Adverse Events Associated with Disease-Modifying Drugs for Multiple SclerosisNeurol 102:e208006, Ng, HS.,et al, 2024
Newer Agents in the Treatment of Multiple SclerosisNeurologist 19:104-117, Pawate, S. & Bagnato F., 2015